A M Sadowska
Overview
Explore the profile of A M Sadowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadowska A, Nowe V, Janssens A, Boeykens E, De Backer W, Germonpre P
Ther Adv Med Oncol
. 2011 Sep;
3(4):207-18.
PMID: 21904581
Lung cancer is the leading cause of cancer deaths worldwide. Standard chemotherapy has been shown to improve quality of life and has a modest influence on overall survival. This modest...
2.
Sadowska A, Klebe B, Germonpre P, De Backer W
Steroids
. 2006 Dec;
72(1):1-6.
PMID: 17145070
Inhaled corticosteroids (ICS) are the standard of care in asthma and are widely used in the treatment of patients with COPD. The influence of steroids on inflammatory processes has long...
3.
Radomska-Lesniewska D, Sadowska A, Van Overveld F, Demkow U, Zielinski J, De Backer W
J Physiol Pharmacol
. 2006 Oct;
57 Suppl 4:325-34.
PMID: 17072061
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation. The initial step in the inflammatory process is overexpression of adhesion molecules, which leads to excessive transmigration of neutrophils....
4.
Sadowska A, Manuel-Y-Keenoy B, De Backer W
Pulm Pharmacol Ther
. 2006 Feb;
20(1):9-22.
PMID: 16458553
In order to develop efficient therapeutic regimes for chronic obstructive pulmonary disease (COPD), N-acetylcysteine (NAC) has been tested as a medication which can suppress various pathogenic processes in this disease....
5.
Sadowska A, Manuel-Y-Keenoy B, De Backer W
Pulm Pharmacol Ther
. 2005 Jun;
18(5):354-62.
PMID: 15939314
Background: Beta2-agonists and glucocorticosteroids are two common treatments for COPD and they are often used in combination. Glucocorticosteroids mediate the anti-inflammatory response through the glucocorticosteroid receptors (GRs). Beta2-agonists are potent...
6.
Sadowska A, Van Overveld F, Gorecka D, Zdral A, Filewska M, Demkow U, et al.
Respir Med
. 2005 Feb;
99(2):241-9.
PMID: 15715193
Background: Chronic obstructive pulmonary disease (COPD) is accompanied by both airway and systemic inflammation and by oxidative stress. This study aimed to characterise the relationship between oxidative stress and inflammatory...
7.
Sadowska A, Van Overveld F, Luyten C, Germonpre P, De Backer W
Inflamm Res
. 2004 Apr;
53(4):143-9.
PMID: 15060720
Objective: The increase in adhesion molecule expression during the initial phase of inflammation leads to transmigration of neutrophils. Inhibition of this transmigration could decrease inflammatory response and tissue damage. Materials...